Phaseline

Companies › PersonGen BioTherapeutics (Suzhou)

PersonGen BioTherapeutics (Suzhou): clinical trials, targets and expected readouts

3 active drug programs in 3 registered trials: 2 Phase 1, 1 Phase 2; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
PA3-17 injection
anti-CD7 CAR-T cell therapy
CD7Phase 2CD7-positive Relapsed/Refractory T Lymphoblastic Leukemia/LymphomaOct 2027
LV009 Injection
Anti-CD19 CAR-T cell therapy
CD19Phase 1Non-Hodgkin LymphomaDec 2026
TAA06 Injection
B7-H3-targeted CAR-T cell therapy
B7H3Phase 1B7-H3-positive Relapsed/ Refractory NeuroblastomaFeb 2039

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07284927LV009 InjectionPhase 1Non-Hodgkin LymphomaOncologyDec 2026
NCT07188610PA3-17 injectionPhase 2CD7-positive Relapsed/Refractory T Lymphoblastic Leukemia/LymphomaOncologyOct 2027
NCT05562024TAA06 InjectionPhase 1B7-H3-positive Relapsed/ Refractory NeuroblastomaOncologyFeb 2039

Targets

CD7 (1) CD19 (1) B7H3 (1)

Companies with the same targets

Gilead Sciences Bristol-Myers Squibb Chongqing Precision Biotech Allogene Therapeutics Miltenyi Biomedicine Hebei Senlang Biotechnology Amgen AstraZeneca Beijing Yongtai Ruike Biotechnology Company Shanghai Ming Ju Biotechnology

Companies built like this

Hebei Senlang Biotechnology Beijing Yongtai Ruike Biotechnology Company Allotera Therapeutics Juventas Cell Therapy Jiangsu Topcel-KH Pharmaceutical

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.